Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors
International Journal of Molecular Sciences · 08.05.2023 · 24 (9) · 8457
DOI: 10.3390/ijms24098457 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.05.2023. Verfasst von Jung Yoon Jang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, National Research Foundation of Korea (NRF) and funded by the Korean government (MSIT), National Research Foundation of Korea (NRF).
Themen: Onkologische Pflege
Abstract (Originalsprache)
DNA topoisomerases are important enzymes that stabilize DNA supercoiling and resolve entanglements. There are two main types of topoisomerases in all cells: type I, which causes single-stranded DNA breaks, and type II, which cuts double-stranded DNA. Topoisomerase activity is particularly increased in rapidly dividing cells, such as cancer cells. Topoisomerase inhibitors have been an effective chemotherapeutic option for the treatment of several cancers. In addition, combination cancer therapy with topoisomerase inhibitors may increase therapeutic efficacy and decrease resistance or side effects. Topoisomerase inhibitors are currently being used worldwide, including in the United States, and clinical trials on the combination of topoisomerase inhibitors with other drugs are currently underway. The primary objective of this review was to comprehensively analyze the current clinical landscape concerning the combined application of irinotecan, an extensively investigated type I topoisomerase inhibitor for colorectal cancer, and doxorubicin, an extensively researched type II topoisomerase inhibitor for breast cancer, while presenting a novel approach for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.
- Functional Food Materials Research Group, Korea Food Research Institute, Wanju-gun 55365, Republic of Korea.
ORCID-Profile: Jung Yoon Jang, Nam Deuk Kim
Förderung
- Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education
- National Research Foundation of Korea (NRF) and funded by the Korean government (MSIT)
- National Research Foundation of Korea (NRF)
Zitieren
APA
Jang, J. Y., Kim, D., & Kim, N. D. (2023). Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors. International Journal of Molecular Sciences, 24(9), 8457. https://doi.org/10.3390/ijms24098457
Vancouver
Jang JY, Kim D, Kim ND. Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors. International Journal of Molecular Sciences. 2023;24(9):8457. doi:10.3390/ijms24098457
BibTeX
@article{Jang2023,
author = {Jang, Jung Yoon and Kim, Donghwan and Kim, Nam Deuk},
title = {Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {9},
pages = {8457},
doi = {10.3390/ijms24098457}
}
EUVIMED